Latest Breaking News On - லூபின் மருந்துகள் - Page 12 : comparemela.com

Lupin, Phil Inc partner to deliver solutions for patients on Solosec®

Lupin, Phil Inc partner to deliver solutions for patients on SolosecÂ® Lupin, Phil Inc partner to deliver solutions for patients on SolosecÂ® 02 February 2021 | News SolosecÂ® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women Source credit: Lupin Lupin Pharmaceuticals, Inc, a global pharmaceutical company, has announced a partnership with Phil, Inc, which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women. This treatment is designed to deliver a full course of therapy in just one packet.

Deepak thomasJon stelzmillerLupin pharmaceuticals incPhil incLupin pharmaceuticalsதீபக் தாமஸ்லூபின் மருந்துகள் இன்க்பில் இன்க்லூபின் மருந்துகள்

Lupin Announces Partnership with Phil, Inc in Support of SOLOSEC® (secnidazole)

Share this article Share this article MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ Lupin Pharmaceuticals Inc. (Lupin), global pharmaceutical company, announced today a partnership with Phil, Inc., which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet. 1 In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021.

United statesSan franciscoDeepak thomasManjira sharmaJon stelzmillerShweta munjalArvind bothraDigital patient access solutionsLupin pharmaceuticals incDrug administrationLupin incPhil incPhysician researchAmerican college of obstetriciansCorporate communicationsPrnewswire lupin pharmaceuticals inc

Pneumonia Therapeutics Market: Upcoming Trends, Research Developments and Analysis Report to 2026

Search jobs Pneumonia Therapeutics Market: Upcoming Trends, Research Developments and Analysis Report to 2026 Pneumonia is a severe inflammation of the lungs. It can be fatal in some people, particularly the elderly and those with respiratory disorders. COVID-19, a disease caused by a novel coronavirus, can spread to the lungs, causing pneumonia. The disease associated with the new coronavirus was originally referred to as novel coronavirus-infected pneumonia (NCIP). It was renamed COVID-19 by the World Health Organization, short for coronavirus disease in 2019. The ongoing COVID-19 pandemic has a positive impact on the demand patterns in the pneumonia therapeutics industry. According to the research report, the global pneumonia therapeutics market in 2019 was approximately USD 14.99 Billion. The market is expected to grow at a CAGR of 8.00% and is anticipated to reach around USD 25.67 Billion by 2026.

United statesAsia pacificBayer agLupin pharmaceuticals incFree sample copy of researchWorld health organizationMerck co incPfizer incFree sample copyResearch reportNorth americaLatin americaMiddle eastLupin pharmaceuticalsMore informationஒன்றுபட்டது மாநிலங்களில்

Massive Growth in Delirium Tremens (DT) Market Set to Witness Huge Growth by 2027| Lannett, polpharma, Bioindustria L I M , Aspen Holdings, Aspire Group – KSU

a2zJanuary 29, 2021 13 Delirium Tremens (DT) Market report focused on the comprehensive analysis of current and future prospects of the Delirium Tremens (DT) industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Delirium Tremens (DT) market has been done in order to calculate the growth rates for each segment and sub-segments. Get Sample Copy of this report with latest Industry Trend and COVID-19 Impact @:

United statesRepublic ofRoger smithLupin pharmaceuticals incCambrex corporationZ market researchOur research analystOtsuka america pharmaceutical incBal pharmaUnited states incGlaxosmithkline incPharmaceuticals pvtJohnson services incTeva pharmaceuticals united states incAspen holdingsDelirium tremens

Klinefelter Syndrome Treatment Market: Growth Factors Details for Business Development, Key Companies, Current Trends Challenges and Forecast By 2023

Klinefelter Syndrome Treatment Market: Growth Factors Details for Business Development, Key Companies, Current Trends Challenges and Forecast By 2023
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United statesEli lillyAkash anandEndo pharmaceuticals incLupin pharmaceuticals incOffice noKyowa kirin internationalMarket researchResearch newswirePfizer incSee campaignAbbvie incLupin pharmaceuticalsKlinefelter syndrome treatment marketEndo pharmaceuticalsFor free sample copy